



Essential Drugs Company Limited

Statement of Financial Position

As at June 30, 2023

Amount in Taka	Notes	June 30, 2023	June 30, 2022
Non current assets:			
Property, plant & equipment	Annexure-A	2,175,780,245	2,210,133,761
Capital work in progress	6.00	8,117,707,486	7,731,743,112
Deferred tax assets	7.00	169,533,600	116,918,631
		<u>10,463,021,331</u>	<u>10,058,795,504</u>
Current assets:			
Inventories	8.00	3,335,134,100	2,833,717,547
Accounts receivable	9.00	624,107,668	371,110,195
Advances, deposits & prepayments	10.00	5,585,513,069	4,443,243,207
Cash and cash equivalents	11.00	5,175,517,406	5,602,077,951
		<u>14,720,272,243</u>	<u>13,250,148,900</u>
Total assets		<u>25,183,293,574</u>	<u>23,308,944,404</u>
Shareholder's equity:			
Share capital	12.00	1,009,248,500	1,009,248,500
General reserve	13.00	3,755,000,000	3,055,000,000
Revaluation reserve	14.00	1,394,309,477	1,401,306,372
Retained earnings		1,502,198,244	1,343,657,297
		<u>7,660,756,221</u>	<u>6,809,212,169</u>
Long term liabilities:			
Long term loan	15.00	463,205,498	483,405,498
Gratuity payable	16.00	1,588,823,970	1,410,875,850
Advance against GOB contribution	17.00	7,143,796,537	6,803,867,969
		<u>9,195,826,005</u>	<u>8,698,149,317</u>
Current liabilities:			
Accounts payable and accrued expenses	18.00	848,311,832	1,144,416,433
Bank overdraft	19.00	-	21,002,690
Security deposits	20.00	90,387,841	83,787,392
Advance against sales		4,261,337,163	3,758,773,644
Provision for taxation	21.00	3,126,674,512	2,793,602,759
		<u>8,326,711,348</u>	<u>7,801,582,918</u>
Total equity & liabilities		<u>25,183,293,574</u>	<u>23,308,944,404</u>
Net asset value (NAV) per share	32.00	<u>75.91</u>	<u>67.47</u>


Chairman


Director


Managing Director

Name of Firm:

M M Rahman & Co.
Chartered Accountants

Signature of the Auditor:

Name of the Auditor:

Mohammed Forkan Uddin FCA
Managing Partner

Enrolment No.:

886

DVC : 2311040886AS203730
Dhaka, Date : 04-11-2023



এম এম রহমান এন্ড কোং
M M Rahman & Co.
Chartered Accountants




Russell Bedford
taking you further
Member of Russell Bedford International
a global network of independent professional services firms

Essential Drugs Company Limited

Statement of profit or loss and other comprehensive income
For the year ended June 30, 2023

Amount in Taka	Notes	2022-2023	2021-2022
Sales revenue	22.00	9,543,202,489	9,020,079,258
Cost of goods sold	23.00	(7,319,607,760)	(6,570,598,194)
Gross profit		<u>2,223,594,729</u>	<u>2,449,481,064</u>
Administrative expenses	24.00	(1,045,068,434)	(922,424,763)
Selling & distribution expenses	25.00	(18,391,464)	(21,352,115)
Operating expenses		<u>(1,063,459,898)</u>	<u>(943,776,878)</u>
Profit from operation		1,160,134,831	1,505,704,186
Other income	26.00	113,889,795	89,184,212
Financial expenses	27.00	(2,296,116)	(6,831,808)
Loss on foreign exchange fluctuation		-	(37,036,344)
Profit before WPPF and welfare funds		<u>1,271,728,510</u>	<u>1,551,020,246</u>
Workers profit participation fund	28.00	(60,558,500)	(73,858,107)
Profit before tax		<u>1,211,170,010</u>	<u>1,477,162,139</u>
Current tax expenses		(333,071,753)	(439,921,159)
Deferred tax income/ (expenses)	7.00	52,614,969	23,253,215
Income tax expenses	29.00	<u>(280,456,784)</u>	<u>(416,667,944)</u>
Profit after tax		<u>930,713,226</u>	<u>1,060,494,195</u>
Other Comprehensive Income			
Items that will not be reclassified subsequently to profit or loss			
Deferred Tax Income/(Expense)	7.00	-	-
Total Comprehensive Income for the year		<u>930,713,226</u>	<u>1,060,494,195</u>
Earnings Per Share (EPS)	31.00	<u>9.22</u>	<u>10.51</u>


Chairman


Director


Managing Director

Name of Firm:

M M Rahman & Co.
Chartered Accountants

Signature of the Auditor:



Name of the Auditor:

Mohammed Forkan Uddin FCA
Managing Partner

Enrolment No.:

886

DVC : 2311040886AS203730
Dhaka, Date : 04-11-2023



এম এম রহমান এন্ড কোং
M M Rahman & Co.
Chartered Accountants



Russell Bedford
taking you further
Member of Russell Bedford International
a global network of independent professional services firms

Essential Drugs Company Limited

Statement of Changes in Equity
For the year ended June 30, 2023

Particulars	Share Capital	General Reserve	Revaluation Reserve	Retained Earnings	Total
Balance as at 01 July 2022	1,009,248,500	3,055,000,000	1,401,306,372	1,343,657,297	6,809,212,169
Prior year adjustments	-	-	-	-	-
Cash Dividend	-	-	-	(60,554,910)	(60,554,910)
Contribution from GOB	-	-	-	-	-
General Reserve	-	700,000,000	-	(700,000,000)	-
Excess depreciation transferred from revaluation reserve to retained	-	-	(6,996,895)	6,996,895	-
Adjustment during the year	-	-	-	-	-
Deferred tax on excess depreciation on revaluation of PPE	-	-	-	-	-
EDCL Foundation	-	-	-	(18,614,265)	(18,614,265)
Net Profit after Tax	-	-	-	930,713,226	930,713,226
Balance as at 30 June 2023	1,009,248,500	3,755,000,000	1,394,309,477	1,502,198,244	7,660,756,221

Particulars	Share Capital	General Reserve	Revaluation Reserve	Retained Earnings	Total
Balance as at 01 July 2021	1,009,248,500	2,555,000,000	1,410,666,238	845,475,545	5,820,390,283
Prior year adjustments	-	-	-	-	-
Cash Dividend	-	-	-	(50,462,425)	(50,462,425)
Contribution from GOB	-	-	-	-	-
General Reserve	-	500,000,000	-	(500,000,000)	-
Excess depreciation transferred from revaluation reserve to retained	-	-	(8,228,788)	8,228,788	-
Adjustment during the year	-	-	(1,131,078)	1,131,078	-
Deferred tax on excess depreciation on revaluation of PPE	-	-	-	-	-
EDCL Foundation	-	-	-	(21,209,884)	(21,209,884)
Net Profit after Tax	-	-	-	1,060,494,195	1,060,494,195
Balance as at 30 June 2022	1,009,248,500	3,055,000,000	1,401,306,372	1,343,657,297	6,809,212,169

Chairman

Director

Managing Director

Name of Firm:

M M Rahman & Co.
Chartered Accountants

Signature of the Auditor:

Name of the Auditor:

Mohammed Forkan Uddin FCA
Managing Partner
886

Enrolment No.:

DVC : 2311040886AS203730
Dhaka, Date : 04-11-2023




Essential Drugs Company Limited

Statement of cash flows

As at June 30, 2023

	June 30, 2023	June 30, 2022
A. Cash flows from operating activities		
Cash receipts from customers and others	9,906,769,912	9,142,901,737
Cash paid to suppliers, employees and others	(9,348,258,886)	(8,020,045,484)
Cash generated from operations	<u>558,511,025</u>	<u>1,122,856,253</u>
Interest paid	(2,296,116)	(6,831,808)
Income tax paid	(794,698,509)	(710,012,550)
Net cash generated from operations	<u>(238,483,601)</u>	<u>406,011,895</u>
B. Cash flows from investing activities		
Acquisition of fixed assets	(88,254,020)	(79,752,569)
Work In progress	(385,964,375)	(704,732,020)
FDR	-	-
Net cash used in investing activities	<u>(474,218,395)</u>	<u>(784,484,589)</u>
C. Cash flows from financing activities		
Long term loan repayment	(20,200,000)	(10,100,000)
Govt. contribution	339,928,568	635,872,398
Consortium party payment	-	-
Bank overdraft	(21,002,690)	21,002,690
Security deposit	47,970,485	34,209,371
Dividend paid	(60,554,910)	(50,462,425)
Net cash provided by financing activities	<u>286,141,452</u>	<u>630,522,034</u>
Net increase in cash and cash equivalents (A+B+C)	(426,560,543)	252,049,339
Cash and cash equivalents at the beginning of the year	5,602,077,951	5,350,028,612
Cash and cash equivalents at the end of the year	<u>5,175,517,406</u>	<u>5,602,077,951</u>
Net Operating Cash Flow Per share (NOCFPS)	33.00	4.02


Chairman


Director


Managing Director

Name of Firm:

M M Rahman & Co.
Chartered Accountants

Signature of the Auditor:



Name of the Auditor:

Mohammed Forkan Uddin FCA
Managing Partner
886

DVC : 2311040886AS203730
Dhaka, Date : 04-11-2023

Enrolment No.: